Drug Trial Radar · NCT04795531
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
588
Actual
Start
Mar 24, 2021
Primary completion
Jun 23, 2022
Study completion Jun 23, 2022
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Mar 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin degludec taken daily. Participants will get their study medicine in an injection pen. Participants will get a pen for weekly injection and one for daily injection. One will be icodec or degludec and the other will be dummy medicine. The treatment participants get is decided by chance. Participants and the study staff will not know which active medicine they get. The insulin is injected with a needle in a skin fold in the thigh. The study could last for about 8 months. Participants will have 13 clinic visits and 17 phone calls with the study doctor. At 8 clinic visits participants will have blood samples taken. At 4 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Insulin icodecDrug
You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo. Subcutaneously (under the skin) injections
Placebo insulin icodecDrug
You will get a pen for weekly injection and one for daily injection. One will be insulin degludec 100 units/mL and the other will be placebo. Subcutaneously (under the skin) injections
Insulin degludecDrug
You will get a pen for weekly injection and one for daily injection. One will be degludec 100 units/mL and the other will be placebo. Subcutaneously (under the skin) injections
Placebo insulin degludecDrug
You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo. Subcutaneously (under the skin) injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Glycated Haemoglobin (HbA1c)Time frame: Baseline (Week 0), Week 26
Locations
190 sites in 12 countries. Site status is shown where the registry gives one.
Univ of Alabama Birmingham
Birmingham, Alabama
Lakeview Clinical Research, LLC
Guntersville, Alabama
Lynn Institute of the Ozarks
Little Rock, Arkansas
Anaheim Clinical Trials, LLC
Anaheim, California
Advanced Clinical Research/Rancho Paseo Medical Group
Banning, California
American Clinical Trials
Buena Park, California
Med Center Medical Clinic
Carmichael, California
Headlands Research California, LLC
Escondido, California
Valley Research
Fresno, California
Scripps Whittier Diabetes Inst
La Jolla, California
First Valley Medical Group
Lancaster, California
Clinical Trials Research_Sacramento
Lincoln, California
Torrance Clin Res Inst, Inc.
Lomita, California
Providence Clinical Research
North Hollywood, California
Valley Clinical Trials, Inc.
Northridge, California
Desert Oasis Hlthcr Med Group
Palm Springs, California
NorCal Endocrinology and Internal Medicine
San Ramon, California
Diabetes Research Center
Tustin, California
Coastal Metabolic Research Center
Ventura, California
Denver Endocrinology Diabetes and Thyroid Center
Englewood, Colorado
Chase Medical Research LLC
Waterbury, Connecticut
Revival Research
Doral, Florida
Est Cst Inst for Rsrch,Jksnvil
Jacksonville, Florida
Jacksonville Ctr For Clin Res
Jacksonville, Florida
University Of Miami
Miami, Florida
Suncoast Clinical Research, Inc.
New Port Richey, Florida
Florida Institute for Clinical research
Orlando, Florida
Palm Harbor Medical Associates
Palm Harbor, Florida
Suncoast Clinical Research, Inc.
Palm Harbor, Florida
Metabolic Research Institute Inc
West Palm Beach, Florida
Clinical Research of Cent FL
Winter Haven, Florida
Physicians Research Assoc. LLC
Lawrenceville, Georgia
RNA America Health Sciences
Sugar Hill, Georgia
East West Med Res Inst
Honolulu, Hawaii
Elite Clinical Trials
Blackfoot, Idaho
Cedar-Crosse Research Center
Chicago, Illinois
Iowa Diab & Endo Res Center
West Des Moines, Iowa
Cotton-Oneill Diabetes and End
Topeka, Kansas
St Elizabeth Physicians Heart
Covington, Kentucky
Four Rivers Clinical Research Inc
Paducah, Kentucky
Showing 40 of 190 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.